Dana-Farber Cancer Institute

Articles

Dana-Farber Research Fellow Tyler Miller, MD, PhD, Receives £600,000 Grant From the Brain Tumour Charity

November 27th 2023

The Brain Tumour Charity awarded a Junior Fellows grants of £600,000 over four years - the first of its kind - to Dana-Farber Research Fellow Tyler Miller, MD, PhD.

Dual-Action Drug Produces Positive Results in Patients With Advanced Neuroendocrine Tumors, Trial Finds

November 16th 2023

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

Oncology Researchers Raise Ethics Concerns Posed By Patient-Facing Artificial Intelligence

November 13th 2023

In a new paper in JCO Oncology Practice, bioethics researchers at Dana-Farber Cancer Institute call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.

Kidney Cancer Study Shows Improved Outcomes for Patients With Advanced Disease When Treated With Belzutifan Over Everolimus

November 7th 2023

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma, the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

First International Collaborative Member of Dana-Farber Cancer Institute Opens in Brazil With Oncoclínicas Cancer Center

November 2nd 2023

Dana-Farber Cancer Institute, a Harvard Medical School affiliated teaching hospital and one of the world's leading cancer treatment and oncology research institutions, and Oncoclínicas & Co, the largest group dedicated to cancer in Latin America, announce the expansion of their collaboration with the opening of the first Oncoclínicas Cancer Center as an International Collaborative Member of Dana-Farber Cancer Institute.

Bradley Bernstein of Dana-Farber Elected to National Academy of Medicine

October 24th 2023

Bradley Bernstein, MD, PhD, Chair of Cancer Biology at Dana-Farber Cancer Institute, has been elected to the National Academy of Medicine.

Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023

October 18th 2023

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology Congress 2023 in Madrid, Spain.

Study Offers Way to Increase Immune Checkpoint Inhibitor Effectiveness in Patients With MTAP-Deleted Cancers

October 12th 2023

Loss of the “housekeeping” gene methylthioadenosine phosphorylase, or MTAP, is a common event in cancer.

Study Uncovers Function of Mysterious Disordered Regions of Proteins Implicated in Cancer

October 4th 2023

New research from Dana-Farber Cancer Institute researcher Cigall Kadoch, PhD, along with colleagues at Princeton University and Washington University in St. Louis, reveals a key role for intrinsically disordered proteins known as IDRs that are implicated in a wide range of human diseases, from cancer to neurodegeneration

Deep Learning Reveals Valuable Clues About Kidney Cancer in Pathology Slides

September 25th 2023

A team of Dana-Farber researchers has identified a potential new way to assess clinically valuable features of clear cell renal cell carcinoma, a form of kidney cancer, using image processing with deep learning.

Potent Oral Agent Acting as Immunotherapy and Targeted Treatment Produces High Response Rate in Certain Patients

September 22nd 2023

A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies

Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center Forge New Collaboration to Advance Future of Adult Cancer Care; Announce Plans to Build Region’s Only Free-Standing Cancer Hospital

September 15th 2023

Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center announced plans for a comprehensive new collaboration designed to advance the future of cancer care and build the region’s only independent, free-standing inpatient hospital for adult cancer patients.

Origins of Glioma Brain Cancer Found to Be in the Epigenome

July 31st 2023

Researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas– incurable brain tumors– can arise due to changes in the epigenome.

New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing

June 19th 2023

Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.

Study Suggests Lymphoma Patients With Depression or Anxiety Experience Shorter Survival Times

June 9th 2023

Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma had shorter survival times than patients without a mental health diagnosis.

Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting

May 30th 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers.

Dana-Farber Researchers Report on the Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer

May 22nd 2023

People living with HIV remain at higher risk than people living without HIV for developing various cancers that can be treated with immune checkpoint inhibitors.

Three-drug Combination Slows Progression of Advanced Kidney Cancer

May 16th 2023

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

International Study Shows Many Younger Women with Breast Cancer Can Safely Have a Baby

May 9th 2023

A new study published today in the New England Journal of Medicine found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur.

Combination Therapy a Promising Option for Advanced Kidney Cancer Patients Already Treated With Immunotherapy

April 28th 2023

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute’s Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, a VEGF TKI, plus belzutifan, a HIF-2α inhibitor.